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Introduction
G-protein coupled receptors (GPCRs) represent more than 1% of the total mammalian genes. They have been successful during animal evolution to recognize a wide range of stimuli from photon to large glycoproteins (1) (2) (3) . These receptors transduce the extracellular signals in cellular responses via heterotrimeric G proteins.
On the basis of sequence similarity, mammalian GPCRs have been classified into five major classes (3) , but all share a common central domain composed of seven transmembrane helices, the heptahelical domain (HD). This domain is assumed to adopt various active and inactive conformations, the former being stabilized by agonists while the latter are stabilized by inverse agonists (4, 5) . In most cases, these ligands directly interact in the heptahelical domain, but agonists can act within an additional extracellular domain (1, 6) . This is the case of class-III GPCRs (7) (8) (9) (10) .
Class-III GPCRs include receptors for the main neurotransmitters glutamate and GABA as well as receptors for Ca 2+ , sweet taste compounds and pheromones (10) . Their agonist binding domain is homologous to bacterial periplasmic binding proteins involved in the trafficking of ions, amino-acids and sugars in the periplasm of gram-negative bacteria (7, 10, 11) . This was confirmed by the determination of the crystal structure of the mGlu 1 extracellular domain. This domain has a bilobate structure that adopts a closed conformation upon agonist binding in the cleft that separates both lobes (12, 13) , and is often called a "Venus flytrap" module (VFTM).
How agonist binding in the VFTM leads to the activation of the HD remains unknown. However, the determination of the crystal structure of the mGlu 1 VFTM with and without bound glutamate together with the demonstration that these receptors are constitutive dimers (14, 15) lead to a model for activation of class-III GPCRs (10, 12, 16) . Accordingly, agonist binding in at least one VFTM of these dimeric receptors leads to a large conformational change of the dimer of VFTMs, possibly forcing the two HDs to interact with each other differently. This is expected to stabilize their active state. Such a peculiar structural organization of the receptor protein, associated with a very low sequence identity of their HD compared to that of other GPCRs, raised the question of whether or not the HDs of all GPCRs function the same way.
We previously reported that mGlu 1a and mGlu 5 metabotropic glutamate receptors (mGluRs) display constitutive activity (17, 18) . A precise analysis of the constitutive activity of these receptors led us to propose that it resulted from a spontaneous activity of their HD rather than from a spontaneous closure of their VFTM (19) . In agreement with this proposal, the non-competitive antagonists, MPEP and BAY36-7620, which bind in the HD (20, 21) are the only antagonists that display inverse agonist activity.
In the present study we examined whether the HD of such receptors could activate G-proteins in the absence of the VFTM. We found that mGlu 5 HD was able to spontaneously activate Gq-type G-proteins, and that this constitutive activity could be inhibited by the known mGlu 5 inverse agonist. Of interest, the positive modulator of mGlu 5 receptor, although devoid of agonist activity on the wild-type receptor, acted as a full agonist on mGlu 5 HD in the absence of the large extracellular domain. In summary, we provide novel insight on the mechanism of action of negative and positive allosteric modulators of class-III GPCRs. Moreover, our data show that the HD of class-III GPCRs displays constitutive activity and can be positively or negatively regulated by ligands, like any other class-I GPCRs.
Materials and methods

Materials
Glutamic acid was purchased from Sigma. L-Quisqualic acid and MPEP (2- 
Contruction of mGlu 5 mutants
The construction of the N-terminal HA-tagged rat mGlu 5a , pRKG5a-NHA, has been already described (22) . The plasmid expressing the ∆5 mutant was obtained by inserting between the Mlu-I and Xba-I sites of pRK5-NHA, the mGlu 5a cDNA coding for the HD and the C-terminal tail between the residues P568 and the C terminal end obtained by PCR. The final plasmid encodes for a protein possessing the signal peptide of mGlu 5 followed by a HA tag and then by the HD and the intracellular C terminus of mGlu 5a . The same strategy was u sed to generate ∆5∆ that corresponds to the mGlu 5a HD segment between P568 and L864 ( Fig. 1A) .
Cell culture and transfection
HEK293 cells were cultured in Dulbecco's modified Eagle's medium supplemented with 10% FCS and transfected by electroporation as described elsewhere (23) . Ten million cells were transfected with plasmid DNA encoding mGlu 5 (0.6 µg), ∆5 (5 µg), ∆5∆ (5 µg) and completed to a total amount of 10 µg plasmid DNA with pRK6. To avoid any influence of glutamate in the assay medium released by the cells, the high affinity glutamate transporter EAAC1 was also co-transfected with the receptor.
Synthesis of 3,3'-difluorobenzaldazine (DFB)
3,3'-difluorobenzaldazine DFB was synthesized according to Buu-Hoi and Saint-Ruf (24) .
Immunofluorescence
Immunofluorescence assay was carried out as described elsewhere (22) . Briefly, 24 hours after transfection, cells platted on coverslips were washed with PBS and incubated for 90 minutes at 37°C with an anti-HA mouse monoclonal antibody (clone 12CA5; Roche, Basel, Switzerland) at 1.33 µg/mL in PBS and 0.2% gelatine. The primary antibody was then detected with a Cy3 secondary antibody (1 µg/mL) (Jackson ImmunoResearch, West Grove, PA). Coverslips were mounted and observed using a Axiophot2 microscope (Zeiss, LePecq, France).
Cell surface quantification by ELISA
Twenty four hours after transfection, cells were washed twice with PBS, fixed with PBS and 4% paraformaldehyde and incubated for 30 minutes with an anti-HA rat monoclonal antibody (clone 3F10; Roche, Basel, Switzerland) (0.5 µg/mL) in PBS containing 5% FCS. Cells were then incubated with a secondary goat antibody conjugated to peroxydase (Jackson ImmunoResearch, West Grove, PA) (1 µg/mL).
Secondary antibody was detected and quantified by chemiluminescence using Supersignal West Femto (Pierce, Rockford, IL) and a Wallac Victor 2 luminescence counter (Molecular devices, St Gregoire, France). All data represented correspond to means ± SEM from representative experiments performed in triplicate.
Inositol phosphate determination
Results
Expression of wild-type and truncated mGlu 5 receptors
To study the functional properties of mGlu 5 HD, two truncated constructs were created. The first one, ∆5, was obtained by removing the VFTM and the cysteine-rich domain, and the second, ∆5∆, was generated by truncating most of the C-terminal tail of ∆5 ( Fig. 1A ). Both N-terminal HA-tagged truncated mutants were expressed at the cell surface as shown by immunostaining of non-permeabilized cells (Fig. 1B ). Under the same conditions, no fluorescence signal was detected at the surface of control cells transfected with the N -terminal HA-tagged GABA B1 subunit of the GABA B receptor that cannot reach the cell surface alone (25, 26) or with an empty pRK6 plasmid (not shown).
Surface expression of the HA-tagged mGlu 5 , ∆5 and ∆5∆ was then quantified using an ELISA assay. These experiments revealed that, for an equal quantity of plasmid DNA transfected in HEK293 cells, the two truncated mutants were 5 to 10 times less expressed at the cell surface than wild-type receptor (not shown). In order to compare the functional properties of these constructs, conditions were set up to achieve a similar surface expression level as depicted in Fig. 1C .
mGlu 5 , truncated mutants are constitutively active
The G -protein coupling activity of mGlu 5 , ∆5and ∆5∆ was examined by measuring IP accumulation. We found a higher IP formation in cells expressing any of these three constructs compared to mock-transfected cells ( Fig. 2A ). This basal activity represented 291, 211 and 284% of the control IP production, for mGlu 5 , ∆5
and ∆5∆, respectively. Among these three constructs, only the wild-type mGlu 5 could be stimulated by glutamate ( Fig. 2A ). Even when applied at high concentration (up to 10 mM, not shown), glutamate had no effect on the truncated mutants ( Fig. 2A) .
These data show that the removal of the large extracellular domain suppresses the ability of glutamate to activate the receptor, but does not prevent the truncated constructs to activate G-proteins spontaneously.
As mentioned above, the truncated receptors did not reach efficiently the cell surface, and accumulated in the ER. Therefore, it is possible that the observed high basal IP formation was due to the intracellular accumulation of mGlu 5 receptors rather than to a constitutive activity of the receptor at the cell surface. However we found that a longer version of ∆5∆ with 6 additional residues at the C-terminal end did n ot reach the cell surface and accumulated in the ER as shown by immunofluorescence studies and ELISA assays performed on intact and permeabilized cells (data not shown). No high basal IP formation could be measured in cells expressing this construct (data not shown). The same was true for a mGlu 5 chimeric construct bearing the ER retention signal of the GABA B1 receptor subunit (data not shown). This confirmed that the basal activity measured was mostly generated by receptors at the cell surface.
Constitutive activity of ∆5 and ∆5∆ is inhibited by a negative allosteric modulator
The non-competitive antagonist MPEP binds within the HD of mGlu 5 (20, 27) .
This compound, often called a negative allosteric modulator, also inhibits the constitutive activity of mGlu 5 . As observed on the wild-type receptor (48.2 ± 15.1% inhibition, n=8), MPEP also inhibited 42.8 ± 1.5% (n=3) and 46.7 ± 15.3% (n=7) of the basal IP formation measured in cells expressing ∆5 and ∆5∆, respectively ( Fig.   2B ). These effects of MPEP were dose-dependent with IC50 values determined on ∆5 (7.6 ± 6.6 nM, n=3, not shown) or ∆5∆ (10.4 ± 6.6 nM, n=7) similar to that determined on mGlu 5 (8.1 ± 4.3 nM, n=8) ( Fig. 2B ). These data confirm that basal IP formation measured in cells expressing ∆5 or ∆5∆ originates from a constitutive PLC activation by these constructs, and that MPEP does not require the extracellular domain of mGlu 5 to interact with the receptor and acts as an inverse agonist.
Furthermore, these data confirm the correct folding of the mGlu 5 HD in the absence of both the large extracellular domain and the long C-terminal tail.
In contrast to the wild-type receptor, the truncated mutants are activated by a positive allosteric modulator
Recently, positive allosteric modulators of various mGlu receptors have been identified (10, 28, 29) . Such compounds display no or very low agonist activity, but largely potentiate the action of agonists interacting in the VFTM. Analysis of the putative binding site of the mGlu 1 and mGlu 2 modulators suggested that they bind in the HD of these receptors (29, 30) . Very recently, DFB has been reported as a positive allosteric modulator of mGlu 5 (31) . In agreement with this study, we found that DFB did not activate mGlu 5 receptor when care was taken to remove as much as possible glutamate from the medium (Fig. 3 ). However, DFB potentiated the action of glutamate, decreasing its EC 50 value 2 fold (32.2 ± 9.2 (n=9) to 17.4 ± 4.4 µM (n=4) in the absence and presence of 100 µM DFB, respectively) (Fig. 3A) . The same effect was observed with the agonist quisqualate (EC 50 23.1 ± 2.3 (n=5) and 13.1 ± 5.5 nM (n=3) in the absence and presence of DFB, respectively, data not illustrated).
The maximal effect of glutamate was however not modified by DFB. As shown in Fig.3B , DFB potentiated quisqualate-induced activation of mGlu 5 with an EC 50 value of 11.3 ± 1.4 µM. A similar effect of DFB was observed when the Ca 2+ signal was measured in cells expressing mGlu 5 (Fig. 3A) .
The effect of DFB was then examined on the truncated receptors ∆5 and ∆5∆.
In contrast to what was observed with the wild-type receptor, DFB activated directly these constructs (Fig. 4A ). This effect was dose-dependent with an EC 50 value of 12.9 ± 6.3 µM (n=6) (Fig. 4A ) identical to that measured for the potentiating effect on the wild-type receptor (Fig. 3A) . A similar effect was obtained with ∆5 (data not shown). DFB was also able to induce a Ca 2+ signal in cells expressing ∆5 or ∆5∆ 
DFB-induced activity of ∆5∆ is close to the agonist-induced activity of mGlu5
In order to compare the activities of mGlu 5 and ∆5∆, cell surface expression and basal and agonist-induced IP production were measured in cells transfected with various amounts of plasmid DNA. Both basal and glutamate-induced IP productions were directly proportional to the amount of receptors at the cell surface, the slope of the correlation lines being indicative of the specific (amount of IP produced per receptor) basal and glutamate-induced activity of the receptor (Fig. 4C ). When the same analysis was performed with ?5? in the absence and presence of DFB, the same correlation lines were obtained, showing that the specific constitutive activity of ?5? is similar to that of mGlu 5 , and that DFB-induced activity of ?5? is similar to the glutamate-induced activity of the wild-type receptor (Fig. 4C) .
Inhibition of the DFB-induced response of ∆5∆ by MPEP
Since both DFB and MPEP were found to act on ?5?, we examined whether MPEP could inhibit the action of DFB. As shown in Fig. 5 , MPEP inhibited the effect of DFB on IP production or increase in intracellular Ca 2+ in cells expressing ?5?.
However, even at high concentration, MPEP only partly inhibited the effect of DFB on ∆5∆. This indicates a complex interaction between MPEP and DFB binding sites, in agreement with the partial inhibition of [ 3 H]-methoxyPEPy (an analog of MPEP) binding by DFB on the wild-type receptor (31) .
Discussion
The present study demonstrates that mGlu 5 HD can activate PLC in the absence of both the large extracellular domain (the VFTM and the cysteine-rich domain) and the long C-terminal intracellular tail. Indeed, this domain of the mGlu 5 receptor displays a similar constitutive activity as the wild-type receptor. Moreover, we show that the inverse agonist MPEP conserved its activity on this truncated mutant. Finally, our data demonstrate that the positive allosteric modulator DFB is acting as a full agonist on this domain. These data shed light on the possible mechanism of action of such positive allosteric modulators of class-III GPCRs.
Our data clearly indicate that both the inverse agonist MPEP, and the positive allosteric regulator DFB do not need the large extracellular domain of mGlu 5 to exert their action. Indeed, our data indicate that they directly interact within the HD of this receptor, therefore at a site distinct from the orthosteric ligand binding site located in the VFTM (10, 12) . This is in agreement with the proposed binding site of the noncompetitive antagonists of mGlu 5 (MPEP) (20, 27) , and mGlu 1 (21, 30, 32) . Of interest, when a detailed analysis of these antagonists binding sites have been performed by site directed mutagenesis and molecular modeling, the binding pocket was found to be equivalent to that of retinal in rhodopsin (20, 27, 30) . Although positive modulators of mGlu receptors have been identified only recently (28, 29, 31) , one study analyzed the binding site of the mGlu 2 potentiator LY487379 (29) . In that case again, the binding pocket was found to be located within the HD, with important residues located in TM IV and V. In agreement with the latter study, our data also indicate the positive modulator DFB binds in the HD of mGlu 5 . However, the effect of DFB was not fully inhibited by MPEP in agreement with the reported partial inhibition of MPEP binding by DFB (31) . This indicates a complex interaction between these two ligands suggesting they act at different sites. This reinforces the need for a detailed analysis of the DFB site.
Group-I mGluRs, mGlu 1a , mGlu 5a and mGlu 5b display constitutive activity in heterologous expression systems (17, 18) . The absence of inverse agonist activity of competitive antagonists known to prevent VFTM closure lead us to propose that the constitutive activity originates from the HD able to reach an active state even if the VFTM stays open (19, 21) . In agreement w ith this possibility, non-competitive antagonists interacting in the HD have inverse agonist activity (20, 21) . Our present data showing the HD of mGlu 5 displays the same constitutive activity as the wild-type receptor strongly support this idea. A kinetic model recently developed also confirmed this idea and, of interest, showed that the allosteric coupling between the VFTM and the HD is not strict (19) . In other words, the change in conformation of one domain only influences the equilibrium constant between the two states of the other domain, but does not force it to adopt a specific conformation. Such a finding is likely of importance since we recently reported that the constitutive activity of group-I mGluRs is tightly regulated by the intracellular proteins Homer in neurons (33) . As such, group-I mGluRs can be activated either by extracellular glutamate or by the intracellular protein Homer1a. The low allosteric coupling between the HD and the VFTM allows the intracellular protein Homer1a not to increase dramatically glutamate affinity. Thus, the receptor can retain its ability to be further activated by extracellular glutamate in a physiological range of concentration (19) .
Our data confirm that the positive allosteric modulator of mGlu 5 , DFB is devoid of agonist activity on the wild-type receptor (it is not able to activate the full length receptor by itself) (31) . We previously proposed that such a ligand is not able to directly stabilize the active state of the HD, but instead facilitates the active closed state of the VFTM to activate it (19) . This proposal is clearly not consistent with our present data showing DFB activates the HD expressed alone to a similar extent as glutamate on the full length receptor. Accordingly, it appears that the presence of the VFTM prevents DFB from activating the HD, a conclusion not consistent with a weak allosteric coupling between the VFTM and the HD. How can one reconcile these observations? Recent findings revealed GPCRs likely exist in at least 3 states, a Rg (ground) state that corresponds to the totally inactive state stabilized by inverse agonists, a R state that is able to activate G-proteins though with a low efficacy, and a R* state that corresponds to the active state of the receptor stabilized by full agonists (34, 35) . By analogy, we propose the HD of mGlu 5 also exists in these 3 states: HDg, HD and HD*. The equilibrium between HDg and HD may not be controlled by the VFTM. This equilibrium would be at the origin of the observed constitutive activity not inhibited by competitive antagonists, but by non-competitive ones directly acting in the HD (Fig. 6) . In contrast, the HD* state would require the VFTM to be in the active state, such that DFB would not be able to activate the receptor without agonists. In contrast, in the absence of VFTM, the HD would be able to reach more freely the fully active state HD* in the presence of DFB (Fig. 6 ). Since mGluRs are constitutive dimers, it is possible that the HD can oscillate between HDg and HD states when the dimer of VFTMs is in the resting orientation (R in Fig. 6 ). On the other hand, when the dimer of VFTMs is in the active orientation (A in Fig. 6 ), the HD can reach the HD* state that is stabilized by DFB. Accordingly, it is possible that the formation of a specific form of the HD dimer is stabilized by DFB. However, further experiments are required to confirm this proposal.
The periplasmic binding proteins are known to bind their ligand in the periplasmic space and to deliver it to a transmembrane complex responsible for the transport of the molecule inside the bacteria (11, 36) . Among the hypotheses for the activation mechanism of class-III GPCRs, it was proposed that the VFTM would bind the ligand and deliver it to another site within the HD leading to its activation (37) . Our data show that the mGlu 5 HD cannot be activated by glutamate up to a concentration of 10 mM. This is not due to the inability of this domain to be activated since DFB can fully activate this domain. Such an observation favors therefore the second proposal that originates from the crystal structure of the mGlu 1 VFTM (10, 12, 16) . Indeed, this domain forms dimers and a large change in conformation of the dimer is observed upon agonist binding (Fig. 6 ). This is assumed to stabilize a specific conformation of the dimer of associated HDs leading to their activation (Fig. 6 ). As mentioned above, class-III VFTMs are not only involved in ligand binding but also in the dimerization process of these receptors (14, 15, 38) . Such a dimer formation is assumed to be crucial for the intramolecular transduction between the VFTM and the HD (10) .
Whether dimerization of GPCRs is required for G-protein activation is still a matter of intense debate (39) (40) (41) (42) . At least our data show that the stabilization (and even disulfide cross-linking between the subunits) of class-III dimers by the VFTM is not required for the HD to activate G-proteins. Accordingly, either the HD can dimerize by itself, or dimerization is not required for G-protein activation.
There is actually a lot of pharmaceutical interests in identifying new allosteric modulators of mGluRs as potential new therapeutic agents. Our data show that the use of the HD of mGluRs may be a good tool to identify such new ligands since an agonist rather than a positive modulator has to be identified. The group of Conklin also highlighted the potential use of receptor activated solely by synthetic ligands (RASSL) (43) . HDs of mGluRs may constitute new possibilities to develop such tools Top: the constitutive dimer of mGlu 5 is shown to be composed of a VFTM (top), a cystein-rich domain (middle) and a HD. The HD is proposed to oscillate between a 23 slightly active state (HD) and a totally inactive ground state (HDg), the latter being stabilized by inverse agonist. This equilibrium can occur even though the dimer of VFTM stays in the resting state (R). The dimer of VFTMs is assumed to reach an active orientation (A) in the presence of agonist, leading to the stabilization of a fully active state of the dimer of HDs (HD*). The positive allosteric modulator, DFB, is proposed to bind with a higher affinity on HD*, stabilizing the fully active state of the receptor, leading to an increased affinity of the receptor for agonists (19) . Bottom: in the absence of the large extracellular domain, the HD can reach more freely the fully active state HD* allowing the positive modulators to act as full agonists. 
